High density lipoprotein subfractions and the risk of coronary heart disease: 9-Years follow-up in the Caerphilly study

Atherosclerosis

Volumn 166, Issue 2, 2003, Pages 331-338

  Yu, Shicheng ^a   Yarnell, John W G ^a   Sweetnam, Peter ^a   Bolton, Colin H ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Coronary heart disease; HDL cholesterol; HDL subfractions; Prospective study

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIET RESTRICTION; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MALE; POPULATION RESEARCH; PRECIPITATION; PREDICTION; PRIORITY JOURNAL; SAMPLING; STANDARDIZATION;

CHOLESTEROL, HDL; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY DISEASE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 0037299545     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00361-1     Document Type: Article

References (41)

1. Gofman J.W., Young W., Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 34:1966;679-697.
2. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62:1977;707-714.
3. Miller N.E., Thelle D.S., Forde O.H., Mjos O.D. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1:1977;965-968.
4. Enger S.C., Hjermann I., Foss O.P., et al. High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery. 5:1979;170-181.
5. Goldbourt U., Medalie J.H. High density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study. Am. J. Epidemiol. 109:1979;296-308.
6. Goldbourt U., Holtzman E., Neufeld H.N. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br. Med. J. (Clin. Res. Ed.). 290:1985;1239-1243.
7. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev. Med. 15:1986;254-273.
8. Gordon D.J., Knoke J., Probstfield J.L., Superko R., Tyroler H.A. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 74:1986;1217-1225.
9. Manninen V., Huttunen J.K., Heinonen O.P., Tenkanen L., Frick M.H. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am. J. Cardiol. 63:1989;42H-47H.
10. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
11. Pocock S.J., Shaper A.G., Phillips A.N. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. Br. Med. J. 298:1989;998-1002.
12. Yarnell J.W.G., Patterson C.C., Sweetnam P.M., et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Ten-year follow-up of Caerphilly and Speedwell cohorts. Arterioscler. Thromb. Vasc. Biol. 21:2001;1340-1345.
13. Lamarche B., Despres J.P., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Quebec cardiovascular study. Atherosclerosis. 119:1996;235-245.
14. Miller G.T. Lewis B. Lipoproteins, atherosclerosis and coronary heart disease. 1981;59-71 Elsevier, Amsterdam.
15. Musliner T.A., Krause R.M. Lipoprotein subspecies and risk of coronary disease. Clin. Chem. 34:1988;B78-B83.
16. Miller N.E., Hammett F., Saltissi S., et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br. Med. J. (Clin. Res. Ed.). 282:1981;1741-1744.
17. 3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation. 84:1991;129-139.
18. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Engl. J. Med. 325:1991;373-381.
19. 3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 90:1994;769-774.
20. 3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler. Thromb. Vasc. Biol. 17:1997;1098-1105.
21. Fujimoto W.Y., Bergstrom R.W., Boyko E.J., et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care. 22:1999;1808-1812.
22. Gidez L.I., Miller G.J., Burstein M., Slger S., Eder H.A. Separation and quantitation of subclasses of human plasma high density lipoprotein by a simple precipitation procedure. J. Lipid Res. 23:1982;1206-1223.
23. Yarnell J.W.G., Sweetnam P.M., Rumley A., Lowe G.D.O. Lifestyle and hemostatic risk factors for IHD: The Caerphilly Study. Arteriosler. Thromb. Vasc. Biol. 20:2000;271-279.
24. Lowe G.D.O., Yarnell J.W.G., Sweetnam P.M., Rumley A., Thomas H.F., Elwood P.C. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb. Haemost. 79:1998;129-133.
25. Yarnell J.W.G., Baker I.A., Sweetnam P.M., et al. Fibrinogen, viscosity and white blood cell count are major risk factors for ischaemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 83:1991;836-844.
26. Rose G.A., Blackburn H., Gillum R.F., Prineas R.J. Cardiovascular survey methods. 2nd ed :1982;World Health Organization, Geneva.
27. Lopes-Virella M.F., Stone P., Ellis S., Colwell J.A. Cholesterol determinations in high-density lipoprotein separated by three different methods. Clin. Chem. 23:1977;882-884.
28. Steele B.W., Koehler D.F., Kuba K., Azar M.M. An enzymatic approach to lipoprotein quantification. Am. J. Clin. Pathol. 73:1980;75-78.
29. World Health Organization. International classification of diseases: manual of the international statistics classification of diseases, injuries, and causes of death, 9th revision. London: HMSO, 1977.
30. World Health Organization Regional Office for Europe. Myocardial infarction community registers. Copenhagen: WHO; Public Health in Europe, No, 5, 1976.
31. Lane P.W., Nelder J.A. Analysis of covariance and standardization as instances of prediction. Biometrics. 38:1982;613-621.
32. Nie N.H., Hull C.H., Jenkins J.G., Steinbrenner K., Bent D.H. Statistical package for the social sciences: second edition. 1996;McGraw-Hill, London.
33. 3 in serum. Clin. Chim. 32:1986;819-825.
34. Silverman D., Ginsburg G.S., Pasternak R.C. High density lipoprotein subfractions. Am. J. Med. 94:1993;636-645.
35. Miller N.E. Associations of high density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113:1987;587-589.
36. 3 cholesterol and apolipoproteins A-I and B with lifestyle factors in healthy women and men: the Stanford Five City Project. Prev. Med. 31:2000;346-356.
37. 3 cholesterol. Atherosclerosis. 152:2000;503-510.
38. Sweetnam P.M., Bolton C.H., Downs L.G., et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly Study. Eur. J. Clin. Invest. 30:2000;947-956.
39. Gidez LI, Miller GJ, Burstein M, Eder HA. Analysis of plasma high density lipoprotein subclasses by a precipitation procedure: Correlation with preparative and analytical ultracentrifugation, In: Lippel K, editor. Report of the High Density Lipoprotein Methodology Workshop. Washington, DC: Department of Health, Education and Welfare, 1979. p. 328-35, 335X. US Department of Health, Education and Welfare Publication NIH 79-1661.
40. Rader D.J., Castro G., Zech L.A., Fruchart J.C., Brewer H.B. Jr. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpAI, A-II. J. Lipid Res. 32:1991;1849-1859.
41. Parra H.J., Arveiler D., Evans A.E., et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler. Thromb. 12:1992;701-707.